Matthew Pink
VP Business Development Biodesix
Seminars
Thursday 5th February 2026
From Market Insight to Clinical Impact: Developing an Ultra-Sensitive ESR1 ddPCR Assay
11:25 am
- Why ESR1 now: ESR1 has become a time-sensitive, longitudinal ctDNA biomarker, enabling earlier insight into endocrine resistance as ER-targeted therapies expand
- Monitoring needs different tools: Reliable resistance tracking requires ultra-sensitive, reproducible detection at very low allele fractions, positioning ddPCR as a strong fit for longitudinal monitoring
- From insight to action: A real-world case study showing how market and clinical needs translate into a validated ESR1 ddPCR assay that supports meaningful R&D decisions
